Sabrina Serani

Rezatapopt produced responses in 35/76 ovarian cancer patients, comprising 4 confirmed complete responses, 29 confirmed partial responses, and 2 unconfirmed partial responses by RECIST v1.1.

Interim overall survival met a preplanned secondary endpoint, favoring ivonescimab over pembrolizumab in first-line PD-L1 TPS ≥1% advanced NSCLC, with detailed OS metrics forthcoming. Progression-free survival was the primary endpoint and improved from 5.82 months with pembrolizumab to 11.14 months with ivonescimab (HR 0.51; independent radiologic review).

Dr Ryan Funk explains how 2026 CMS coding changes and commercial payer contracts are straining radiation oncology practices, threatening rural and freestanding centers and patient access to care.

New dataset reveals Asian American breast cancer survival advantage persists despite reproductive, lifestyle, neighborhood, and treatment factors, highlighting crucial ethnic and nativity differences.

A City of Hope study found success in promoting skin cancer screening to transplant survivors, Dr Saro Armenian explains.

Confirmed ORR improved with INBRX-106 plus pembrolizumab (48.3%) versus pembrolizumab alone (26.5%), with complete responses seen only with the combination.

For Prostate Cancer Awareness Month, Manojkumar Bupathi, MD, MS, examines how oncologists are changing practice after 4 key FDA approvals and a trend toward biomarker-driven therapy.

The UK's OPTIMUM trial showed significant differences with a more aggressive treatment regimen for high-risk newly diagnosed multiple myeloma, based on long-term follow-up.

Jonathan Villena-Vargas, MD, explains how a subcostal robotic approach avoids intercostal nerve damage, cutting post-thoracotomy pain and opioid use.

David DiBardino, MD, explains why intratumoral therapy emerged in lung cancer and the open questions in standardizing how it's delivered to tumors.